Cytomegalovirus (CMV)–Specific CD4+T Lymphocyte Immune Function in Long‐Term Survivors of AIDS‐Related CMV End‐Organ Disease Who Are Receiving Potent Antiretroviral Therapy

Open Access
Publisher Website
Google Scholar
Abstract
To better understand the relation of cytomegalovirus (CMV)–specific CD4+ T lymphocyte immunity and clinical outcome in AIDS-related CMV end-organ disease, 2 patient groups were prospectively studied: patients recently diagnosed with active CMV end-organ disease and survivors of CMV retinitis who had responded to highly active antiretroviral therapy and had quiescent retinitis when anti-CMV therapy was discontinued. Most patients with active CMV disease had negative CMV-specific CD4+ T lymphocyte responses at diagnosis, as measured by lymphoproliferation (7/7) or cytokine flow cytometry (3/5) assays. In contrast, all 10 subjects with quiescent retinitis and >150 absolute CD4+ T lymphocytes/μL whose anti-CMV therapy was discontinued during 6 months of follow-up had positive CMV-specific immune responses at least once by each assay. However, 6 of these 10 subjects also had negative CMV-specific immune responses ⩾1 time. Such patients may be at risk for future CMV disease progression and should be closely monitored

This publication has 0 references indexed in Scilit: